Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EPO Analyses May Give J&J Fodder To Protect Procrit From Aranesp

Executive Summary

Two recently released studies could help Johnson & Johnson in its efforts to ward off competition for its anemia therapy Procrit (epoetin) from Amgen's second-generation erythropoietin product Aranesp (darbepoetin)

You may also be interested in...



Amgen Plans Seven ESA Risk Studies After Latest Safety Update To Labeling

Amgen is expanding its pharmacovigilance program for Aranesp and Epogen with seven new clinical trials to study risks associated with using erythropoiesis-stimulating agents to treat anemia in patients with cancer

Amgen Plans Seven ESA Risk Studies After Latest Safety Update To Labeling

Amgen is expanding its pharmacovigilance program for Aranesp and Epogen with seven new clinical trials to study risks associated with using erythropoiesis-stimulating agents to treat anemia in patients with cancer

Investors Judge Biotech Harshly: PDL BioPharma, MedImmune, Amgen Disappoint

Biotechnology investors could experience palpitations after this past quarter's dismal performance on the "The Pink Sheet" Index of NASDAQ stocks

Related Content

UsernamePublicRestriction

Register

OM011381

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel